title: Successful long-term treatment with the bradykinin B2 receptor antagonist icatibant in a patient with hereditary angioedema.
abstract: BACKGROUND
  Hereditary angioedema (HAE) is a rare, autosomal dominant disorder caused by a C1-esterase inhibitor (C1-INH) deficiency (type 1) or qualitative defect (type 2). It is characterized by recurrent subcutaneous or submucosal edema attacks in various organs with a frequency from a few attacks to over one hundred attacks per year.
  
  
  METHODS
  We report on the treatment of 141 attacks in a patient with hereditary angioedema with the bradykinin B2 receptor antagonist icatibant.
  
  
  RESULTS
  During the entire observation period, efficacy of icatibant was maintained and not altered due to repeated administrations. No systemic or cardiovascular side affects were observed.
  
  
  CONCLUSIONS
  In the present case, icatibant proved to be an effective and safe drug for the symptomatic treatment of acute HAE attacks. Its efficacy was not impaired by repeated administrations over a three-year period in this patient.
authors.affiliation: Department of Otorhinolaryngology, University Hospital Essen, University Duisburg, Essen, Germany. jens.greve@uk-essen.de
authors.forename: Jens
authors.initials: J
authors.lastname: Greve
authors.forename: Thomas K
authors.initials: TK
authors.lastname: Hoffmann
authors.forename: Patrick
authors.initials: P
authors.lastname: Schuler
authors.forename: Stephan
authors.initials: S
authors.lastname: Lang
authors.forename: Adam
authors.initials: A
authors.lastname: Chaker
authors.forename: Murat
authors.initials: M
authors.lastname: Bas
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage* / Q000627:therapeutic use; D001920:Bradykinin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D065094:Bradykinin B2 Receptor Antagonists; D017326:Clinical Trials, Phase III as Topic; D004334:Drug Administration Schedule; D056829:Hereditary Angioedema Types I and II / Q000188:drug therapy*; D006801:Humans; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D065094:Bradykinin B2 Receptor Antagonists; C065679:icatibant; D001920:Bradykinin